Premium
Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide‐based combination chemotherapy
Author(s) -
Kinoshita Mariko,
Yamada Ai,
Sawa Daisuke,
Kamimura Sachiyo,
Miyachi Mitsuru,
Moritake Hiroshi
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26750
Subject(s) - temozolomide , medicine , vincristine , alveolar rhabdomyosarcoma , rhabdomyosarcoma , irinotecan , cyclophosphamide , chemotherapy , cancer research , radiation therapy , oncology , methyltransferase , methylation , gene , pathology , cancer , sarcoma , biology , biochemistry , colorectal cancer
A 3‐year‐old male presented with a large retroperitoneal mass and multiple metastases. Biopsy results suggested alveolar rhabdomyosarcoma bearing a methylated O6‐methylguanine‐DNA methyltransferase ( MGMT ) gene promoter. Serum microRNA‐206 levels were elevated and remained high after three cycles of vincristine, dactinomycin, and cyclophosphamide (VAC). Replacement of vincristine, irinotecan, and temozolomide (VIT) for VAC induced a marked tumor reduction and normalization of the miR‐206 levels. The patient completed 14 cycles of VIT with local radiotherapy and has been in remission for 31 months. Temozolomide could be effective for tumors with a methylated MGMT gene promoter. Individualized therapy is warranted for such patients.